Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109394 · ClinicalTrials.gov registry record
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
A clinical trial of Sarcoma and Neuroblastoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 6,035
- Enrollment target
- 5
- Study locations
NCT01109394 is a study of Sarcoma and Neuroblastoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 6,035 participants, above the 872-participant average among 122 other Sarcoma trials with a reported enrollment target (592% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT01109394, a study of Sarcoma and Neuroblastoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 6,035 participants
- Enrollment target
- 5
- Study locations
Study Summary
Background: \- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system. Objectives: \- To collect and store blood, serum, tissue, urine, or tumor samples of children who have cancer or adults who have common childhood cancers. Eligibility: * Individuals who have been diagnosed with a common childhood cancer (e.g., leukemia) regardless of patient age. * Children, adolescents, and adults who have been diagnosed with a type of cancer more commonly found in adults. Design: * Extra blood, serum (the liquid part of blood), tissue, urine, or tumor samples will be collected from participants at a time when sampling is required for medical care or as part of a research study. * No additional procedures will be performed for the sole purpose of obtaining additional tumor tissue, aside from what is required for clinical care.
Conditions Studied
Study Locations (5)
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Children's Hospital of Orange County (CHOC Children's) - Orange
Maryland
- National Institutes of Health Clinical Center - Bethesda
New York
- Tisch Cancer Institute, Mount Sinai Medical Center - New York
North Carolina
- Carolinas Medical Center/Levine Children's Hospital - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,035 participants |
| Start Date | 2010-04-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01109394
The ClinicalTrials.gov registry entry for NCT01109394 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 6,035 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 872-participant average among 122 other Sarcoma trials with a reported enrollment target (592% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Sarcoma appearing as the primary indexed condition, and to 0 interventions.
NCT01109394 reports 5 study locations spanning 5 distinct geographic areas - top geographies include District of Columbia, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT01109394 about?
NCT01109394 is a clinical study titled "Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies". Background: \- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additio...
What is the current status of trial NCT01109394?
This trial is currently recruiting. The enrollment target is 6,035 participants. The study started on 2010-04-21.
What conditions does trial NCT01109394 study?
This clinical trial studies the following conditions: Sarcoma, Neuroblastoma, Renal Cancer, Retinoblastoma, Endocrine Tumors.
Who is sponsoring clinical trial NCT01109394?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01109394 being conducted?
This trial has 5 study locations across District of Columbia, Florida, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.